Logo

Celltrion's Regdanvimab Receives the EC's Approval for the Treatment of COVID-19

Share this

Celltrion's Regdanvimab Receives the EC's Approval for the Treatment of COVID-19

Shots:

  • The EC has granted marketing authorisation for Celltrion's regdanvimab in adults with COVID-19 who do not require supplemental oxygen & are at high risk of progressing to severe COVID-19
  • The approval is based on the P-III trial to evaluate the efficacy & safety of regdanvimab in 1315+ patients with COVID-19 across 13 countries including the US, Spain & Romania. The results showed a 72% reduction in risk of COVID-19 related hospitalization or death in high-risk patients
  • The company is currently discussing with the US FDA regarding submission of an application for a EUA & has reported the development of a neutralizing Ab cocktail with CT-P59 against new emerging variants of SARS-CoV-2

 Ref: Celltrion | Image: Celltrion 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions